Shahzad Raza, MD, discusses the phase 2 RedirecTT-1 study which investigated the combination of talquetamab and teclistamab for treating patients with relapsed/refractory multiple myeloma complicated ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

The comeback story of belantamab mafodotin (Blenrep) hit a roadblock Thursday as the FDA's Oncologic Drugs Advisory Committee ...

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or ...

This new Shingrix vaccine presentation eliminates the need for reconstitution, simplifying the administration process for ...

Following in the footsteps of other pharmaceutical companies, Bristol Myers Squibb and Pfizer are offering Eliquis for cash-paying patients at a discount of 40% off the list price.

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.